Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Total Non-Current Liabilities (2018 - 2025)

Plus Therapeutics (PSTV) has disclosed Total Non-Current Liabilities for 11 consecutive years, with $7.3 million as the latest value for Q2 2025.

  • Quarterly Total Non-Current Liabilities changed N/A to $7.3 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Jun 2025, changed N/A year-over-year, with the annual reading at $9.1 million for FY2020, 40.11% down from the prior year.
  • Total Non-Current Liabilities for Q2 2025 was $7.3 million at Plus Therapeutics, down from $10.6 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $10.6 million in Q1 2025, with the low at $7.3 million in Q2 2025.